Literature DB >> 26297546

Upregulation of miR-556-5p promoted prostate cancer cell proliferation by suppressing PPP2R2A expression.

Wei Zhao1, Longbin Cao2, Sha Zeng3, Haiping Qin3, Tongyi Men4.   

Abstract

The prognosis and survival rate of prostate cancer are very poor. Previous studies have shown that miR-556-5p have emerged as important regulators in cancer cell biological processes. The role of miR-556-5p in prostate cancer remains unclear. In this study, expression of miR-556-5p in prostate cancer cell lines and tissues was upregulated. Result of MTT assays, colony formation and anchorage-independent growth assays demonstrated that overexpression of miR-556-5p promoted prostate cancer cell growth. Additionally, PPP2R2A was identified as a direct target of miR-556-5p. Ectopic expression of miR-556-5p led to downregulation of PPP2R2A protein, which resulted in the downregulation of p27, upregulation of cyclin D1. Taken together, our data provide compelling evidence that miR-556-5p functions as an onco-miRNA and participates in prostate cancer carcinogenesis by suppressing PPP2R2A expression.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cell proliferation; PPP2R2A; Prostate cancer; miR-556-5p

Mesh:

Substances:

Year:  2015        PMID: 26297546     DOI: 10.1016/j.biopha.2015.07.015

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

1.  miR-660 promotes liver cancer cell proliferation by targeting PPP2R2A.

Authors:  Yaozhen Pan; Lei Zhan; Ling Chen; Liwen Chen; Chengyi Sun
Journal:  Exp Ther Med       Date:  2021-04-25       Impact factor: 2.447

2.  MiR-556-5p modulates migration, invasion, and epithelial-mesenchymal transition in breast cancer cells via targeting PTHrP.

Authors:  Rongjun Zhou; Zhen Luo; Guanqun Yin; Lanting Yu; Hao Zhong
Journal:  J Mol Histol       Date:  2022-01-09       Impact factor: 2.611

3.  PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN.

Authors:  Xiaodan Chong; Jingde Chen; Nanxin Zheng; Zhuqing Zhou; Yanan Hai; Shiqing Chen; Yu Zhang; Qingzhuo Yu; Shijun Yu; Zhiqin Chen; Wenfang Bao; Ming Quan; Zhe-Sheng Chen; Yangyang Zhan; Yong Gao
Journal:  Mol Cancer       Date:  2022-05-26       Impact factor: 41.444

4.  Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

Authors:  David C Wedge; Gunes Gundem; Thomas Mitchell; Dan J Woodcock; Inigo Martincorena; Mohammed Ghori; Jorge Zamora; Adam Butler; Hayley Whitaker; Zsofia Kote-Jarai; Ludmil B Alexandrov; Peter Van Loo; Charlie E Massie; Stefan Dentro; Anne Y Warren; Clare Verrill; Dan M Berney; Nening Dennis; Sue Merson; Steve Hawkins; William Howat; Yong-Jie Lu; Adam Lambert; Jonathan Kay; Barbara Kremeyer; Katalin Karaszi; Hayley Luxton; Niedzica Camacho; Luke Marsden; Sandra Edwards; Lucy Matthews; Valeria Bo; Daniel Leongamornlert; Stuart McLaren; Anthony Ng; Yongwei Yu; Hongwei Zhang; Tokhir Dadaev; Sarah Thomas; Douglas F Easton; Mahbubl Ahmed; Elizabeth Bancroft; Cyril Fisher; Naomi Livni; David Nicol; Simon Tavaré; Pelvender Gill; Christopher Greenman; Vincent Khoo; Nicholas Van As; Pardeep Kumar; Christopher Ogden; Declan Cahill; Alan Thompson; Erik Mayer; Edward Rowe; Tim Dudderidge; Vincent Gnanapragasam; Nimish C Shah; Keiran Raine; David Jones; Andrew Menzies; Lucy Stebbings; Jon Teague; Steven Hazell; Cathy Corbishley; Johann de Bono; Gerhardt Attard; William Isaacs; Tapio Visakorpi; Michael Fraser; Paul C Boutros; Robert G Bristow; Paul Workman; Chris Sander; Freddie C Hamdy; Andrew Futreal; Ultan McDermott; Bissan Al-Lazikani; Andrew G Lynch; G Steven Bova; Christopher S Foster; Daniel S Brewer; David E Neal; Colin S Cooper; Rosalind A Eeles
Journal:  Nat Genet       Date:  2018-04-16       Impact factor: 38.330

Review 5.  Translational applications of microRNAs in cancer, and therapeutic implications.

Authors:  Grace T Kwok; Jing Ting Zhao; Jocelyn Weiss; Nancy Mugridge; Himanshu Brahmbhatt; Jennifer A MacDiarmid; Bruce G Robinson; Stan B Sidhu
Journal:  Noncoding RNA Res       Date:  2017-12-20

6.  RETRACTED: LSAMP-AS1 binds to microRNA-183-5p to suppress the progression of prostate cancer by up-regulating the tumor suppressor DCN.

Authors:  Xing Hua; Zhen Liu; Min Zhou; Yan Tian; Pei-Pei Zhao; Wen-Hai Pan; Chao-Xia Li; Xiao-Xiao Huang; Ze-Xiao Liao; Qi Xian; Bo Chen; Yue Hu; Lei Leng; Xiao-Wei Fang; Li-Na Yu
Journal:  EBioMedicine       Date:  2019-11-12       Impact factor: 8.143

7.  Knock-down of microRNA miR-556-5p increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via activating NLR family pyrin domain containing 3 (NLRP3)-mediated pyroptotic cell death.

Authors:  Feng Shi; Luquan Zhang; Xing Liu; Yue Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  MicroRNA-139-5P inhibits human prostate cancer cell proliferation by targeting Notch1.

Authors:  Qian Sun; Danhui Weng; Kezhen Li; Shuang Li; Xiangyang Bai; Can Fang; Danfeng Luo; Peng Wu; Gang Chen; Juncheng Wei
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

9.  Analysis of change in microRNA expression profiles of lung cancer A549 cells treated with Radix tetrastigma hemsleyani flavonoids.

Authors:  Peigang Liu; Xu Yang; Hongjian Zhang; Jinbao Pu; Kemin Wei
Journal:  Onco Targets Ther       Date:  2018-07-24       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.